Acinetobacter pneumonia is pneumonia caused by gram-negative coccobacillus bacteria from the Acinetobacter species, with the majority of clinical infections caused by bacteria from the Acinetobacter baumannii-calcoaceticus (ABC) complex, which includes Acinetobacter baumannii, Acinetobacter calcoaceticus, Acinetobacter nosocomialis, and Acinetobacter pittii.

Acinetobacter predominantly infects critically ill patients in hospital, often resulting in severe pneumonia and bloodstream infections. Other body sites such as the urinary tract and the skin may also be affected.

Acinetobacter has demonstrated ability to acquire multidrug resistance, with resistance to penicillins, and almost all antibiotics used to treat Gram-negative bacteria, including fluoroquinolones, aminoglycosides, cephalosporins, and carbapenems.

Xacduro (sulbactam for injection and durlobactam for injection) is the first targeted therapy FDA approved to treat hospital-acquired and ventilator-associated pneumonias caused by caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex.

Drugs used to treat Acinetobacter Pneumonia